While BM PC bind type I IFN receptor-blocking antibody anifrolumab, it is to a lesser degree than circulating B cells. Anti-nuclear autoantibodies (ANA) are found in the BM supernatant and PBL serum ...

Opens in a new tab or window The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease (CLE, lupus skin disease) than two other commonly used therapies, ...

Currently, there is no approved and accessible vaccine for plague, which remains a life-threatening endemic disease in global regions (WHO R&D blueprint, 2018). In recent years, significant advances ...